Cargando…
Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands
The use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in ci...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677586/ https://www.ncbi.nlm.nih.gov/pubmed/33240849 http://dx.doi.org/10.3389/fchem.2020.587207 |
_version_ | 1783612006924812288 |
---|---|
author | Tong, Ka-Chung Hu, Di Wan, Pui-Ki Lok, Chun-Nam Che, Chi-Ming |
author_facet | Tong, Ka-Chung Hu, Di Wan, Pui-Ki Lok, Chun-Nam Che, Chi-Ming |
author_sort | Tong, Ka-Chung |
collection | PubMed |
description | The use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in cisplatin, is of great interest but it is inherently unstable and redox-reactive under physiological conditions. Coordination ligands containing C and/or N donor atom(s) such as porphyrin, pincer-type cyclometalated and/or N-heterocyclic carbene (NHC) can be employed to stabilize gold(III) ion for the preparation of anticancer active compounds. In this review, we described our recent work on the anticancer properties of gold(III) compounds and the identification of molecular targets involved in the mechanisms of action. We also summarized the chemical formulation strategies that have been adopted for the delivery of cytotoxic gold compounds, and for ameliorating the in vivo toxicity. |
format | Online Article Text |
id | pubmed-7677586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76775862020-11-24 Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands Tong, Ka-Chung Hu, Di Wan, Pui-Ki Lok, Chun-Nam Che, Chi-Ming Front Chem Chemistry The use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in cisplatin, is of great interest but it is inherently unstable and redox-reactive under physiological conditions. Coordination ligands containing C and/or N donor atom(s) such as porphyrin, pincer-type cyclometalated and/or N-heterocyclic carbene (NHC) can be employed to stabilize gold(III) ion for the preparation of anticancer active compounds. In this review, we described our recent work on the anticancer properties of gold(III) compounds and the identification of molecular targets involved in the mechanisms of action. We also summarized the chemical formulation strategies that have been adopted for the delivery of cytotoxic gold compounds, and for ameliorating the in vivo toxicity. Frontiers Media S.A. 2020-11-06 /pmc/articles/PMC7677586/ /pubmed/33240849 http://dx.doi.org/10.3389/fchem.2020.587207 Text en Copyright © 2020 Tong, Hu, Wan, Lok and Che. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Chemistry Tong, Ka-Chung Hu, Di Wan, Pui-Ki Lok, Chun-Nam Che, Chi-Ming Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands |
title | Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands |
title_full | Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands |
title_fullStr | Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands |
title_full_unstemmed | Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands |
title_short | Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands |
title_sort | anticancer gold(iii) compounds with porphyrin or n-heterocyclic carbene ligands |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677586/ https://www.ncbi.nlm.nih.gov/pubmed/33240849 http://dx.doi.org/10.3389/fchem.2020.587207 |
work_keys_str_mv | AT tongkachung anticancergoldiiicompoundswithporphyrinornheterocycliccarbeneligands AT hudi anticancergoldiiicompoundswithporphyrinornheterocycliccarbeneligands AT wanpuiki anticancergoldiiicompoundswithporphyrinornheterocycliccarbeneligands AT lokchunnam anticancergoldiiicompoundswithporphyrinornheterocycliccarbeneligands AT chechiming anticancergoldiiicompoundswithporphyrinornheterocycliccarbeneligands |